Spravato
Our ongoing series on medications takes the jump into next-generation treatments
The Frontier Psychiatrists is a daily health-themed publication. I’ve been writing an extremely popular series for a very tiny niche audience on medications. This started as an attempt to explain what I could for my colleagues about the treatments I was no longer excited to use…I’ve jumped ship to lean into neuromodulation-first care at Fermata, the clinic I co-run in Brooklyn, New York, and at Acacia Clinics, in Sunnyvale California, where I also work.
You can request information about psychiatric care with my team here!
Esketamine is the first FDA-approved “psychedelic-like” compound. The parent compound, Ketamine, is a dissociative anesthetic agent, about which I have senior-authored a review1, available in the American Journal of Therapeutics. I started working with Esketamine back in 2019, if memory serves, and have done research (as a Principal Investigator) related to safety and monitoring technology powered by AI.2
Now that the above study has been published, I’m free to write t…